ES2581277T3 - Composición mejorada para inhibir la proliferación de células tumorales - Google Patents

Composición mejorada para inhibir la proliferación de células tumorales Download PDF

Info

Publication number
ES2581277T3
ES2581277T3 ES11702471.1T ES11702471T ES2581277T3 ES 2581277 T3 ES2581277 T3 ES 2581277T3 ES 11702471 T ES11702471 T ES 11702471T ES 2581277 T3 ES2581277 T3 ES 2581277T3
Authority
ES
Spain
Prior art keywords
cds
tumor
proinflammatory
mature
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11702471.1T
Other languages
English (en)
Spanish (es)
Inventor
Alex Karlsson-Parra
Bengt Andersson
Annacarin Wallgren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendus AB
Original Assignee
Immunicum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunicum AB filed Critical Immunicum AB
Application granted granted Critical
Publication of ES2581277T3 publication Critical patent/ES2581277T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES11702471.1T 2010-02-10 2011-02-10 Composición mejorada para inhibir la proliferación de células tumorales Active ES2581277T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US303153P 2001-07-05
US30315310P 2010-02-10 2010-02-10
SE1050133 2010-02-10
SE1050133 2010-02-10
PCT/EP2011/051952 WO2011098516A1 (en) 2010-02-10 2011-02-10 Improved composition for inhibiting tumor cell proliferation

Publications (1)

Publication Number Publication Date
ES2581277T3 true ES2581277T3 (es) 2016-09-05

Family

ID=43903832

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11702471.1T Active ES2581277T3 (es) 2010-02-10 2011-02-10 Composición mejorada para inhibir la proliferación de células tumorales

Country Status (13)

Country Link
US (1) US9034317B2 (cg-RX-API-DMAC7.html)
EP (1) EP2534242B1 (cg-RX-API-DMAC7.html)
JP (1) JP5855018B2 (cg-RX-API-DMAC7.html)
KR (1) KR101770785B1 (cg-RX-API-DMAC7.html)
CN (1) CN102782123B (cg-RX-API-DMAC7.html)
BR (1) BR112012019267B1 (cg-RX-API-DMAC7.html)
DK (1) DK2534242T3 (cg-RX-API-DMAC7.html)
ES (1) ES2581277T3 (cg-RX-API-DMAC7.html)
HU (1) HUE028352T2 (cg-RX-API-DMAC7.html)
PL (1) PL2534242T3 (cg-RX-API-DMAC7.html)
RU (1) RU2565542C2 (cg-RX-API-DMAC7.html)
SI (1) SI2534242T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011098516A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2668816C2 (ru) * 2012-12-18 2018-10-02 Иммуникум Аб Совместная дифференцировка моноцитов от аллогенных доноров
PT3291821T (pt) * 2015-05-07 2026-03-18 Baylor College Medicine Imunoterapêutica com células dendríticas
CN105462926A (zh) * 2015-12-31 2016-04-06 深圳市中美康士生物科技有限公司 一种免疫细胞瘤苗的制备方法及其应用
CN105695403A (zh) * 2015-12-31 2016-06-22 深圳市中美康士生物科技有限公司 一种杀伤性免疫细胞的培养方法及其应用
CN107574149B (zh) * 2016-07-05 2022-02-18 上海细胞治疗研究院 一种树突状细胞的促成熟方法及其用途
CN106085960A (zh) * 2016-07-28 2016-11-09 广州赛莱拉干细胞科技股份有限公司 一种培养dc细胞的培养基及培养方法
EP3516045A1 (en) * 2016-09-23 2019-07-31 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
GB201711379D0 (en) 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
HUE047540T2 (hu) * 2017-09-20 2020-04-28 Immunicum Ab Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1840206A1 (en) 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
WO2008110569A1 (en) * 2007-03-12 2008-09-18 Bioneer A/S Method for determination of immunomodulatory effect
JP2010539993A (ja) * 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
US8728806B2 (en) * 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
CN101481677B (zh) * 2009-01-22 2011-12-14 复旦大学附属华山医院 体外刺激树突状细胞成熟的方法

Also Published As

Publication number Publication date
RU2012137173A (ru) 2014-03-20
US9034317B2 (en) 2015-05-19
KR101770785B1 (ko) 2017-08-23
US20120328662A1 (en) 2012-12-27
EP2534242A1 (en) 2012-12-19
CN102782123A (zh) 2012-11-14
SI2534242T1 (sl) 2016-08-31
JP2013519363A (ja) 2013-05-30
EP2534242B1 (en) 2016-04-20
DK2534242T3 (en) 2016-07-18
BR112012019267B1 (pt) 2022-03-03
PL2534242T3 (pl) 2016-11-30
WO2011098516A1 (en) 2011-08-18
KR20120114358A (ko) 2012-10-16
JP5855018B2 (ja) 2016-02-09
HUE028352T2 (en) 2016-12-28
CN102782123B (zh) 2016-05-11
BR112012019267A2 (pt) 2020-10-06
RU2565542C2 (ru) 2015-10-20

Similar Documents

Publication Publication Date Title
Ke et al. Bifunctional fusion membrane‐based hydrogel enhances antitumor potency of autologous cancer vaccines by activating dendritic cells
DK2534242T3 (en) Improved composition for the inhibition of tumor cell proliferation
ES2535835T3 (es) Composiciones para la preparación de células dendríticas maduras
US10946080B2 (en) Compositions and methods for combination therapy with dengue virus and dendritic cells
WO2021228832A1 (en) Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
ES2923769T3 (es) Procedimientos relacionados con composiciones de células dendríticas activadas para sujetos con cánceres avanzados
CN105007930B (zh) 用于治疗疾病的同种异体自噬体富集组合物
CN103861107B (zh) 一种药物组合物及其用途
Weiden et al. Robust antigen-specific T cell activation within injectable 3D synthetic nanovaccine depots
ES2927913B2 (es) Composición que comprende una combinación de las furanocumarinas psoraleno y angelicina y su uso en terapia
Hu et al. A lymph node-targeted cell-nanoadjuvant conjugate enhances dendritic cell-T cell crosstalk for cancer immunotherapy
Salem et al. Synergistic combination of murine bone marrow-derived dendritic cells loaded ex vivo with whole tumor lysate and systemic chemotherapy mediates antitumor immune responses in vivo
RU2637631C2 (ru) Способ иммунотерапии хронического вирусного гепатита с
Li An injectable, spontaneously assembling biomaterial-based cancer vaccine platform
Mousavi et al. Application of Regenerative Medicine in the Treatment and Management of COVID-19
CN121868479A (zh) 一种负载肿瘤抗原的cd83阳性树突状细胞制剂及其制备方法和应用
Koshy Injectable Biomaterial Systems for Immuno-oncology